益气复脉注射液联合阿伐他汀治疗冠心病慢性心力衰竭疗效及对sCD40、sCD146、PAPP-A的影响

Effect of Yiqi Fumai Injection Combined with Atorvastatin on Chronic Heart Failure Patients with Coronary Heart Disease and Its Effects on sCD40, sCD146 and PAPP-A

目的:分析益气复脉注射液联合阿伐他汀治疗冠心病慢性心力衰竭患者的疗效及对CD40、CD146、PAPP-A的影响。方法:118例冠心病慢性心力衰竭患者,根据数字表法随机分成两组,每组59例。对照组患者采用阿伐他汀治疗,观察组患者采用益气复脉注射液联合阿伐他汀治疗。观察两组患者治疗前后心功能分级变化;治疗前后LVEF、LVDD、NO、NT-proBNP水平及sCD40、sCD146、PAPP-A水平;用药后不良反应情况。结果:治疗后,观察组患者心功能与对照组相比明显改善,差异有统计学意义(P<0.05);观察组LVEF(40.08±2.86)%、LVDD(51.56±7.19)mm、NT-proBNP水平(1145.17±88.47)pg/mL、sCD40(8.01±2.10)ng/mL、sCD146(184.14±9.63)ng/mL、PAPP-A(2.22±0.72)mU/L明显低于对照组LVEF(46.09±3.93)%、LVDD(57.51±7.90)mm、NT-proBNP水平(1898.53±98.68)pg/mL、sCD40(10.89±2.15)ng/mL、sCD146(190.23±9.21)ng/mL、PAPP-A(3.72±0.80)mU/L,而NO水平(384.21±12.38)μmol/L高于对照组(307.51±13.52)μmol/L,差异有统计学意义(P<0.05)。观察组用药后不良反应发生率(6.78%)明显低于对照组(20.34%),差异有统计学意义(P<0.05)。结论:采用益气复脉注射液联合阿伐他汀治疗冠心病慢性心力衰竭患者效果显著,能有效改善心功能,重塑心室肌,降低sCD40、sCD146、PAPP-A水平,不良反应少,有利于患者预后。

Objective: To analyze the effect of Yiqi Fumai Injection combined with atorvastatin on patients with chronic heart failure of coronary heart disease and the effect on CD40, CD146 and PAPP-A. Methods: A total of 118 patients with CHD were randomly divided into two groups according to the digital table method, with 59 cases in each group. The control group was treated with atorvastatin, while the observation group was treated with Yiqi Fumai Injection combined with atorvastatin. The changes of cardiac function in the two groups were observed before and after treatment, and the levels of LVEF, LVDD, NO, NT-proBNP and sCD40, sCD146 and PAPP-A before and after treatment, and the adverse reactions after treatment. Results: After treatment, the cardiac function of the observation group was significantly improved compared with that of the control group(P<0.05). The observation group’s LVEF(40.08±2.86)%, LVDD(51.56±7.19)mm, NT-proBNP(1145.17±88.47)pg/mL, sCD40(8.01±2.10)ng/mL, sCD146(184.14±9.63)ng/mL and PAPP-A(2.22±0.72)mU/L were significantly lower than LVEF(46.09±3.93)%, LVDD(57.51±7.90)mm, NT-proBNP level(1898.53±98.68)pg/mL, sCD40(10.89±2.15)ng/mL, sCD146(190.23±9.21)ng/mL, PAPP-A(3.72±0.80)mU/L of the control group, while the NO level(384.21±9.21) was higher than that of the control group. The difference was statistically significant(P<0.05). The incidence of adverse reactions after treatment in the observation group(6.78%) was significantly lower than that in the control group(20.34%), and the difference was statistically significant(P<0.05). Conclusion: The effect of Yiqi Fumai Injection combined with atorvastatin on patients with chronic heart failure of coronary heart disease is significant. It can effectively improve cardiac function, reshape ventricular muscle and reduce the levels of sCD40, sCD146 and PAPP-A, with less adverse reactions, beneficial to the prognosis of patients.